Pharmaceutical revenue analysis has a core problem that most financial models paper over with a line item called ‘gross-to-net adjustments.’ This number—representing rebates, chargebacks, co-pay assistance, and other price concessions—has grown from a modest footnote to, in some drug categories, the dominant determinant of whether a manufacturer’s pricing action translates into actual revenue. MedPricer’s cross-dataset architecture does not eliminate the opacity of the rebate ecosystem, but it provides the external validation layer that has been missing from most analyst models: a way to confirm, or contradict, what manufacturers report about the trajectory of their own price realization.
Why Manufacturers Cannot Fully Explain the Gap
Gross-to-net adjustments are not a single contract but the aggregate of hundreds or thousands of individual arrangements: formulary rebates, performance-based contracts, government program discounts (Medicaid best price, 340B, VA federal ceiling price), chargebacks from wholesalers, and manufacturer-funded co-pay assistance programs. The legal and contractual frameworks governing most of these arrangements prohibit their detailed disclosure. A manufacturer can tell you that gross-to-net adjustments were ‘approximately 50%’ of list revenue. They cannot tell you whether that 50% is driven by Medicaid statutory rebates, PBM formulary arrangements, or 340B pricing obligations.
This opacity is not unique to any one company—it is structural to the U.S. pharmaceutical market. And it creates an information asymmetry that disadvantages every analyst attempting to model forward revenue from a WAC pricing action.
ASP as an Independent Verification Tool
ASP data, for drugs reimbursed under Medicare Part B, provides an independent, CMS-validated measure of manufacturer net revenue. Because ASP is calculated from manufacturer-reported sales net of most price concessions, a manufacturer whose reported gross-to-net is 40% should show an ASP approximately 60% of WAC. When the math does not work—when ASP implies a gross-to-net spread substantially larger or smaller than what the manufacturer reports—that discrepancy deserves explanation.
MedPricer makes this comparison systematically possible. For any Part B drug in the dataset, the WAC-to-ASP ratio is directly observable over time. A manufacturer reporting stable gross-to-net while the WAC-ASP spread is widening in MedPricer’s data has an inconsistency worth interrogating in the next earnings call.
The Therapeutic Category Question
Gross-to-net dynamics vary significantly across therapeutic categories, in ways that matter for competitive analysis. Oncology drugs administered in physician offices have historically carried smaller gross-to-net spreads than primary care drugs competing for PBM formulary placement. The Part B reimbursement environment and physician purchasing economics differ fundamentally from the managed care PBM environment governing primary care.
MedPricer’s ability to filter and compare WAC-ASP spreads by therapeutic category creates the possibility of category-level competitive analysis: which drug classes are experiencing the fastest gross-to-net expansion, which are stable, and what the cross-category patterns suggest about where formulary negotiation leverage currently lies. That kind of analysis is not available from any single manufacturer’s disclosure.
The Limit of What External Data Can Reveal
ASP data covers Part B. Most branded drugs are Part D or commercially covered, where no equivalent independent price signal exists. The gross-to-net problem for Part D drugs—and for the commercially insured population—remains essentially unobservable from external data. MedPricer’s analytical edge exists primarily in the Part B drug space and in the generic market, where NADAC provides a reasonable acquisition cost proxy.
For large-cap pharma with significant Part B revenue, that is still a substantial fraction of the drug universe. For Part D-dominant companies, the WAC-ASP approach provides directional signal but not comprehensive coverage. Analysts using MedPricer’s dataset should be precise about which segments of a manufacturer’s revenue the cross-benchmark signal actually illuminates—and which remain in the dark.
